AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Follow-Up Questions
AC Immune SA 的 CEO 是誰？
Prof. Dr. Andrea Pfeifer 是 AC Immune SA 的 Chief Executive Officer，自 2003 加入公司。
ACIU 股票的價格表現如何？
ACIU 的當前價格為 $3.01，在上個交易日 increased 了 2.06%。
AC Immune SA 的主要業務主題或行業是什麼？
AC Immune SA 屬於 Biotechnology 行業，該板塊是 Health Care
AC Immune SA 的市值是多少？
AC Immune SA 的當前市值是 $302.3M
AC Immune SA 是買入、賣出還是持有？
據華爾街分析師稱，共有 6 位分析師對 AC Immune SA 進行了分析師評級，包括 4 位強烈買入，4 位買入，1 位持有，0 位賣出，以及 4 位強烈賣出
